All In Biotech

Investigational drug · Phase 3

Opevesostat

Also called: MK-5684, ODM-208

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer Metastatic, Malignant Neoplasm, Metastatic Castration-resistant Prostate Cancer (mCRPC).

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

7 still active

All registered trials

12

Any phase or sponsor naming "Opevesostat"

First trial start

2018

Mar 19, 2018

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Opevesostat", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Prostate Cancer Metastatic
  • Malignant Neoplasm
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Prostatic Neoplasms
  • Prostatic Neoplasms, Castration-Resistant
  • Castration-Resistant Prostatic Cancer
  • Metastasis
  • Metastatic Castration-resistant Prostate Cancer

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Opevesostat" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for Prostate Cancer Metastatic

  • CyclophosphamidPhase 33 trials

    Alentis Therapeutics AG · Glomerulonephritis Rapidly Progressive, Diffuse Large B-Cell Lymphoma (DLBCL), Metastatic Colorectal Cancer

  • luxdegalutamideJSB462, ARV-766Phase 24 trials

    Novartis · Prostatic Cancer, Castration-Resistant, Progressive Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer Metastatic

  • ADI-212Phase 21 trial

    Adicet Therapeutics · Prostate Cancer Metastatic

  • CC-38Phase 21 trial

    CuraCell TX AB · Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.